Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U S Patent License Agreement With Viralliance Inc: related news

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich.--(BUSINESS WIRE)--Jul 4, 2008 - ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich.--(BUSINESS WIRE)--July 4, 2008--ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich. - ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, roya

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

Health & Fitness : Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling...

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling (TrueMill) CAMARILLO, Calif., Aug. 19 /PRNewswire/ -- Surfware, Inc., developer of innovative CAD/CAM software for machining, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its Engagement Milling technology. A Notice of Allowance signifies that the application has been examined and is allowed for issuance as a patent. The U.S. Patent Office accepted all key aspects of the company's patent application. "We are pleased to receive this Notice of Allowance because it serves to protect the intellectual property and proprietary technology that we have developed," says Stephen Diehl, President and CEO of Surfware.

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc. The '978 patent covers the Company's approved product, SANCTURA XR(TM), a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder. Based on calculations made by the United States Patent and Trademark Office, the term of the '978 patent is twenty years plus 89 days from its filing date of November 4, 2004, or February 1, 2025. In September 2007, the Company entered into an agreement with Allergan, Inc. by which the Company granted Allergan an exclusive sublicense to market SANCTURA XR in the United States.

ABL signs patent licensing agreement with Viralliance

ABL Patent Licensing Technologies, a subsidiary of Advanced Biological Laboratories, has entered into a patent licensing agreement with Viralliance.

Drugs industry protecting 'morally unacceptable' patent system

Add our medical news to digg - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to NewsVine - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Fark - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Furl - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Shadows - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to YahooMyWeb - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Reddit -Drugs industry protecting 'morally unacceptable' patent system Add our medical news to StumbleUpon - Drugs industry protecting 'morally unacceptable' patent system Add our medical news to Facebook - Drugs industry protecting 'morally unaccep

Silence Therapeutics Announces Successful Opposition of Glover Patent

a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety. The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule. Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc.

Santarus Announces Issuance Date of Additional U.S. Patent

Santarus, Inc. SNTS, a specialty pharmaceutical company, today announced that its licensor, the University of Missouri, has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent application number 10/641,732 will issue on July 15, 2008 as U.S. patent number 7,399,772. The new patent has claims covering methods for treating acid-caused gastrointestinal disorders by administering a solid pharmaceutical composition comprising non-enteric coated omeprazole and certain antacids. A Notice of Allowance was sent by the USPTO in April 2008. The new patent will have a July 2016 expiration date.

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio

Health Discovery Corporation (HDVY), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive industry.

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio

Health Discovery Corporation (OTCBB:HDVY), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive industry.

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio

SAVANNAH, Ga. - (Business Wire) Health Discovery Corporation (OTCBB:HDVY), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive

Health Discovery Corporation Inks Agreement with Patent Profit International for Monetization of Patent Portfolio

SAVANNAH, Ga. (Business Wire) -- Health Discovery Corporation (OTCBB:HDVY), a leader in support vector machine (SVM) based molecular diagnostic and prognostic test development today announced the signing of an Agreement with Patent Profit International (PPI), a Silicon Valley-based patent brokerage firm, with the goal of exploiting the full monetization potential of HDC's extensive pioneering patent portfolio. Under the agreement, PPI will market HDC's patent portfolio, which includes exclusive rights to SVM techniques and applications that reach far beyond biomarker discovery and the Healthcare Field, to prospective buyers/licensees in a wide range of technologies, including, but not limited to, information technology such as Internet browsers and search engines, spam mail detection, oil exploration, homeland security, and the automotive

Search took 0.86 seconds.